



National Board of Examinations - Journal of Medical Sciences
Volume 4, Issue 5, Pages 651–654, May 2026
DOI 10.61770/NBEJMS.2026.v04.i05.002

EDITORIAL

India's Critical Transition from Exploratory Stem Cell Research to Scalable, Evidence-Based Regenerative Medicine & The Role of National Biobank Repositories

Minu Bajpai^{1,*} and Abhijat C. Sheth²

¹*Vice-President & Honorary Executive Director, National Board of Examinations in Medical Sciences, New Delhi*

²*Chairman of National Medical Commission & President, National Board of Examinations in Medical Sciences, New Delhi*

Accepted: 4-May-2026 / Published Online: 6-May-2026

India's engagement with stem cell science has traversed a remarkable arc—from early exploratory research to the threshold of clinically meaningful, technology-driven regenerative medicine. Yet, the next phase of evolution will not be defined merely by incremental scientific advances, but by the country's ability to **translate biological promise into scalable, evidence-based, and equitable healthcare solutions**. This transition is

being shaped by converging technological trajectories—gene editing, tissue engineering, artificial intelligence, and advanced manufacturing—while simultaneously demanding the creation of robust foundational infrastructure. Among these, **national biobank repositories stand out as a strategic cornerstone**, enabling precision, reproducibility, and acceleration of translational pipelines.

India must develop a tiered national biobank architecture. At the apex would be a National Biobank Grid responsible for governance, standard setting, and interoperability. Regional biobanks would handle processing and storage, while institutional nodes—located in medical colleges and hospitals—would serve as collection points. Integration with digital health systems, unique identifiers for samples, and dynamic consent frameworks will be essential to ensure traceability, ethical compliance, and data security.

*Corresponding Author: Minu Bajpai

Email: bajpai2b@gmail.com

At present, India occupies a distinctive position in the global regenerative medicine landscape. It benefits from a large and diverse patient population, expanding clinical research capacity, and a strong base of academic and translational institutions. National guidelines developed by the Indian Council of Medical Research and the Department of Biotechnology have provided a regulatory scaffold, although implementation variability persists. Importantly, while hematopoietic stem cell transplantation remains the only widely accepted standard therapy, multiple other applications—ranging from orthopaedic regeneration to neurological repair—are being actively explored. The critical question, therefore, is not whether India can innovate, but whether it can **scale innovation responsibly and efficiently**.

The future trajectory of stem cell research in India will be anchored in **precision regenerative medicine**. The advent of induced pluripotent stem cells (iPSCs) has fundamentally altered the therapeutic paradigm, allowing patient-specific cell lines to be generated, manipulated, and potentially reintroduced with minimal immunogenicity. In a country characterised by immense genetic heterogeneity, this opens unprecedented opportunities for **population-scale precision medicine**. Disease modelling using patient-derived cells can inform not only individualised therapies but also

public health strategies tailored to specific genetic subgroups.

In parallel, stem cell science is converging **with gene editing technologies**, particularly CRISPR-based platforms. This integration is poised to transform the management of inherited disorders such as thalassemia and other hemoglobinopathies, which are highly prevalent in India. The emergence of **cell-gene hybrid therapies**—where defective genes are corrected *ex vivo* and reintroduced through stem cell platforms—signals a shift from symptomatic management to potential cures. However, such advances also demand stringent regulatory oversight, robust manufacturing systems, and long-term safety monitoring.

Another transformative trajectory lies in the development of **organoids and advanced disease models**. Stem cell-derived organoids—miniaturised, functional representations of organs—are rapidly becoming indispensable tools for drug discovery, toxicity testing, and understanding disease pathophysiology. In the Indian context, organoid technology holds particular promise for studying infectious diseases, metabolic disorders, and cancers that exhibit unique regional patterns. By reducing dependence on animal models and enhancing translational relevance, organoids can significantly accelerate the journey from laboratory discovery to clinical application.

The future of stem cell research in India will be determined not only by scientific breakthroughs but by the systems that enable their translation into practice. Biobanks, by linking biology with data and clinical outcomes, will play a central role in this transformation. They will determine how quickly discoveries move from bench to bedside, how effectively therapies are tailored to patients, and how reliably outcomes are measured and improved.

Closely related is the field of **tissue engineering and 3D bioprinting**, which aims to reconstruct or replace damaged tissues using a combination of stem cells, biomaterials, and engineering principles. While fully functional organ replacement remains a long-term goal, nearer-term applications such as cartilage repair, skin regeneration for burns, and vascular grafts are already within reach. Given India's burden of trauma, chronic disease, and organ failure, these technologies have the potential to address substantial unmet clinical needs.

Equally important is the emergence of **cell-free regenerative therapies**, particularly those based on exosomes and extracellular vesicles. These approaches circumvent many of the challenges associated with live cell transplantation, including immunogenicity and complex storage requirements. Their relative simplicity and scalability make them particularly attractive for a resource-constrained healthcare system, and they may represent the first wave of regenerative therapies to achieve widespread adoption in India.

The industrialization of stem cell therapies represents another defining trajectory. The field is moving away from bespoke, patient-specific interventions toward **standardized, allogeneic “off-the-shelf” products** that can be manufactured at scale. This shift necessitates the development of **GMP-compliant manufacturing ecosystems**, automation technologies, and rigorous quality control systems. For India, achieving cost-effective scale will be essential to ensure that regenerative therapies do not remain confined to elite institutions but become accessible across the health system.

Overlaying all these developments is the growing role of **artificial intelligence and data science**. AI-driven analytics can optimize cell differentiation protocols, predict therapeutic outcomes, and refine clinical trial design. However, the effectiveness of such tools depends on the availability of high-quality, well-annotated datasets—a requirement that brings biobanks' role into sharp focus.

National biobank repositories are no longer passive storage facilities; they are **active engines of translational science**. By systematically collecting, processing, and storing biological samples—along with associated clinical and genomic data—biobanks provide the raw material for discovery, validation, and innovation. In the context of regenerative medicine, their importance is multifaceted.

First, biobanks enable **standardization and reproducibility**, which are essential for scientific credibility. Variability in sample quality and processing protocols has long been a barrier to reproducible research. A nationally coordinated biobank system, operating under uniform standards, can address this challenge and facilitate multicentric collaboration.

Second, they are central to **precision medicine**. Large-scale biobanks capturing the genetic and phenotypic diversity of India's population can support biomarker discovery, patient stratification, and the development of targeted therapies. This is particularly important in a country where disease patterns and treatment responses vary widely across regions and communities.

Third, biobanks play a critical role in **clinical trials and evidence generation**. Longitudinal sample collection allows

researchers to track disease progression, therapeutic response, and long-term outcomes. When integrated with clinical trial networks, biobanks can significantly enhance the quality and depth of evidence generated.

Fourth, they serve as a **resource for manufacturing pipelines**. Access to well-characterized cell lines and donor tissues is essential for the development of GMP-grade products. A robust biobank infrastructure can thus directly support the scaling of regenerative therapies.

However, significant challenges remain. Biobanking is resource-intensive, requiring sustained investment in infrastructure, cold-chain logistics, and data management systems. Ethical concerns related to consent, privacy, and data sharing must be addressed through transparent and robust governance mechanisms. Moreover, the success of biobanks depends on a skilled workforce, including biobank managers, data scientists, and quality assurance specialists—roles that are currently in limited supply.

Policy action must therefore be proactive and strategic. A **National Biobank Mission**, aligned with a broader regenerative medicine strategy, could provide the necessary impetus. Public-private partnerships can help distribute costs and enhance sustainability, while mandatory linkage of biobanking with clinical trials can ensure continuous data generation. Capacity-building programs must be instituted to develop the human

resources required to manage and utilise these repositories effectively.

The integration of biobanks with other elements of the regenerative medicine ecosystem—such as clinical trial networks, manufacturing hubs, and digital health platforms—will be critical. Only through such integration can India create a **learning health system**, where data generated at the point of care feeds back into research and innovation, creating a virtuous cycle of continuous improvement.

India's opportunity is significant. With its scale, diversity, and growing scientific capacity, the country is uniquely positioned to become a global leader in regenerative medicine. However, realizing this potential will require a shift from fragmented efforts to a **coordinated, mission-driven approach**. Investment in biobank infrastructure, integration of translational pipelines, and alignment of policy, regulation, and practice are essential steps in this direction.

In conclusion, the next decade will define India's trajectory in regenerative medicine. If the country succeeds in building a **data-rich, ethically governed, and technologically integrated ecosystem**, it can deliver not only cutting-edge therapies to its population but also set global benchmarks for affordability and scale. National biobank repositories will be at the heart of this transformation—serving as the connective tissue that binds discovery, development, and delivery into a unified, impactful whole.